RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.

About the Regulatory Profession

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Regulatory Code of Ethics

One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.

Regulatory Competency Framework

Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.

Regulatory Convergence

Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.

The report chronicles the huge number of issues-some of them particularly egregious-that have occurred in recent years at facilities responsible for manufacturing pharmaceutical products. The problem is especially prominent at facilities that manufacture sterile injectable drugs, which have experienced widespread shortages in the last two years.

It's easy to see why those shortages have occurred, explained The Times. "In the last three years, six of the major manufacturers of sterile injectable drugs &hellip; have been warned by the&nbsp;Food and Drug Administration&nbsp;(FDA) about serious violations of manufacturing rules."

Four of those facilities have closed or reduced their production capacities, leading to widespread shortages for some essential injectable anti-cancer drugs like Doxil.

But the problems go far beyond just injectables. As noted by The Times and a congressional report, "Nearly a third of the industry's manufacturing capacity is off line because of quality issues."

The problems vary depending on the facility, said experts consulted in the article. Some of the factories are old and in need of repair. Others-generic manufacturers, mostly-don't have the funding to make required upgrades to their facilities due to low profit margins. Some just don't have good quality manufacturing plans in place or are short-staffed due to layoffs.

But the problems have been far from minor. Barrels of human urine, rusty tools used in manufacturing and insects in manufacturing areas have all been found at facilities in the last three years. Worse, FDA inspectors have found products contaminated with mold, fungus, bacteria, human hair and insects-all of which could cause severe adverse events or death.

While some facilities are scrambling to upgrade their facilities in the wake of FDA's crackdown on poor manufacturing practices, the costs are tremendous and the timeline long. Ohio-based Ben Vanue, whose facility was suspended after FDA found significant violations of current good manufacturing practices (cGMP), has invested hundreds of millions of dollars to bring its facility up to standards, but the entire process could take as long as five years.

In the meantime, shortages are likely to persist, which could pose a different set of problems. Such shortages have been associated with the rise of compounding pharmacies, which have been used to fill gaps left by more established manufacturers. Those facilities, however, are not as tightly regulated by FDA, and one-Massachusetts-based New England Compounding Center-has been blamed for a massive outbreak of meningitis that has sickened hundreds and killed 19 patients injected with one of its products. In working to fix one problem, critics argue, FDA may have inadvertently caused even worse ones.